Press coverage about Madrigal Pharmaceuticals (NASDAQ:MDGL) has been trending somewhat negative recently, according to Accern. The research group ranks the sentiment of media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Madrigal Pharmaceuticals earned a news impact score of -0.09 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 46.7184342627938 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Here are some of the news articles that may have impacted Accern Sentiment Analysis’s rankings:
- Madrigal Pharmaceuticals (MDGL) & Raptor Pharmaceutical (RPTP) Critical Comparison (americanbankingnews.com)
- Madrigal Pharmaceuticals, Inc. (MDGL) Analysts See $-0.68 EPS – Gоldmаn Blоg (blog) (goldmanblog.com)
- Roth Capital Reiterates Buy on Madrigal Pharma (MDGL) Following 4Q and Clinical Confusion – StreetInsider.com (streetinsider.com)
- Madrigal Pharmaceuticals (MDGL) Downgraded to “Buy” at BidaskClub (americanbankingnews.com)
- Madrigal Pharmaceuticals (MDGL) Presents At 38th Annual Cowen and Company Healthcare Conference – Slideshow (seekingalpha.com)
Madrigal Pharmaceuticals stock opened at $113.81 on Monday. Madrigal Pharmaceuticals has a 12-month low of $13.09 and a 12-month high of $154.75.
MDGL has been the topic of several research reports. Zacks Investment Research raised Madrigal Pharmaceuticals from a “hold” rating to a “buy” rating and set a $94.00 price objective on the stock in a research report on Wednesday, December 20th. BidaskClub raised Madrigal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 20th. Roth Capital boosted their price target on Madrigal Pharmaceuticals from $82.00 to $170.00 and gave the stock a “buy” rating in a research report on Monday, December 11th. Evercore ISI boosted their price target on Madrigal Pharmaceuticals from $65.00 to $140.00 and gave the stock an “outperform” rating in a research report on Thursday, December 7th. Finally, HC Wainwright boosted their price target on Madrigal Pharmaceuticals from $54.00 to $105.00 and gave the stock a “buy” rating in a research report on Wednesday, December 6th. One analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $154.20.
ILLEGAL ACTIVITY WARNING: “Madrigal Pharmaceuticals (NASDAQ:MDGL) Getting Somewhat Negative Press Coverage, Study Finds” was published by BBNS and is owned by of BBNS. If you are viewing this piece on another website, it was copied illegally and republished in violation of United States and international trademark & copyright law. The original version of this piece can be accessed at https://baseballnewssource.com/2018/03/19/somewhat-negative-media-coverage-somewhat-unlikely-to-impact-madrigal-pharmaceuticals-mdgl-share-price/2015779.html.
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc, formerly Synta Pharmaceuticals Corp., is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH). The Company’s lead product, MGL-3196, is a Phase II-ready once-daily, oral, liver-directed selective thyroid hormone receptor-b (THR-b) agonist for the treatment of NASH, and heterozygous and homozygous familial hypercholesterolemia (FH).
Receive News & Ratings for Madrigal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Madrigal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.